drugset / Trial / NCT00133887

TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients

NCT00133887

Phase 3 Completed 77 enrolled Hospices Civils de Lyon
RandomizedParallel-groupOpen-labelTreatment

Summary

In a population of kidney transplant recipients having developed a first squamous cell carcinoma, the aim of the study is to assess the incidence of subsequent skin cancers over 2 years in patients who are switched to rapamycin as compared to patients who are maintained under calcineurin inhibitors.

Timeline

Start
2004-04
Primary completion
2011-03
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 3 mg
Subject Sirolimus Small molecule 5 mg
Comparator Ciclosporine Unknown
Comparator Tacrolimus Small molecule

Indications